AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

NIAID

HIV Vaccine and Cure Research Highlights from IAS 2015

"8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015).
Vancouver, Canada.
Copyright: Marcus Rose/IAS
Image Shows: (WEPL01) Co-chair: Quarraisha Abdool Karim, Centre for the AIDS Programme of Research in South Africa, South Africa"

As the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) came to a close in Vancouver, Canada, we spoke one last time by Skype with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), to learn about some of the…

PrEP and Additional Benefits of HIV Treatment Among Science Highlights from IAS 2015

"8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015).
Vancouver, Canada.
Copyright: Marcus Rose/IAS
Image Shows: (WEPL01) Co-chair: Quarraisha Abdool Karim, Centre for the AIDS Programme of Research in South Africa, South Africa"

More HIV research findings were shared yesterday as the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) continued in Vancouver, Canada. We spoke by Skype with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), to learn about some of…

CDC and NIH Share PrEP Research at IAS 2015

IAS2015 logo crop2

New findings on pre-exposure prophylaxis (PrEP) from both CDC and NIH were among the HIV research findings shared on July 21 at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada.  Below are highlights of some of the information they have shared. CDC Study Finds High Adherence…

NIH’s Dr. Carl Dieffenbach Shares Highlights as IAS 2015 Begins

IAS2015 logo crop2

After the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) got underway in Vancouver, Canada yesterday, July 20, we spoke by Skype with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). He shared some highlights from the first full…

Early Antiretroviral Therapy Prevents Non-Aids Outcomes in HIV-Infected People, NIH-Supported Study Finds

NIH logo

New Findings Illustrate Manifold Benefit of Therapy Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to…

HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus

NIH logo

NIH-Funded Trial Proves Suppressive Antiretroviral Therapy for HIV-infected People Effective in Protecting Uninfected Partners ​Antiretroviral treatment that consistently suppresses HIV is highly effective at preventing sexual transmission of the virus in heterosexual couples where one person is HIV-infected and the other is not, investigators report today at the 8th International AIDS Society Conference on HIV…

Next Week: Video Highlights of HIV Science Presented at IAS 2015

IAS2015_web_logo

The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) takes place next week in Vancouver, Canada. For those not able to be there in person, NIH’s Dr. Carl Dieffenbach has agreed to offer scientific highlights via video posts here on blog.aids.gov. Dr. Dieffenbach, who is Director of the Division of…

Curing Hard-to-Treat Hepatitis C

hepc_crop

In a new video, NIH researchers and their colleagues from health centers in the District of Columbia discuss efforts to improve treatments for hepatitis C, a potentially life-threatening viral disease that slowly damages the liver. NIH-sponsored clinical studies in the nation’s capital focus on identifying effective, safe, and convenient therapies for hard-to-treat hepatitis C patients,…